Reading the tape
NASDAQ: EOLS
Evolus, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Market Cap
$363.03M
52w High
$12.16
52w Low
$3.86
P/E
-8.38
Volume
1.97M
Outstanding Shares
65.06M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
1Y Price: -53.54%Revenue (TTM): 9.42%FCF (TTM): -42.98%P/S: 4th pct
What changed
The stock fell 53.54% over the last year. Revenue grew 9.42% over the trailing twelve months. Operating margin moved from -14.76% to -9.57%. Free cash flow declined 42.98% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -9.57%. A decisive move in revenue — currently up 9.42% — would be the clearest signal to resolve the ambiguity.
Company profile
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.
CEODavid Moatazedi
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees372
IPO dateFeb 8, 2018
Valuation
Forward P/E—
EV/EBITDA-18.36
Enterprise value$529.89M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth6.17%
Gross margin65.66%▼5.26%vs FY2024
Operating margin-9.57%▲2.09%vs FY2024
ROE223.5%▲124.48%vs FY2024
Analyst consensus
RatingBuy
Target price$15.00▲168.82%
11
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 4, 2026
Q3 FY26 · EPS est -$0.03 · Revenue est $82.15M
View